What is NanoSyrinx?
NanoSyrinx specializes in the development of protein nanosyringes, a novel delivery mechanism engineered to transport biologic drugs directly into the interior of cells. This platform technology is specifically designed to overcome the limitations of traditional antibodies and peptides, which frequently fail to reach their intended intracellular targets. By unlocking these previously undruggable spaces, NanoSyrinx is effectively expanding the scope of modern medicine. The company operates at the intersection of synthetic biology and drug discovery, maintaining a focus on high-impact therapeutic applications that require precise, targeted delivery systems to ensure efficacy and safety in clinical settings.
How much funding has NanoSyrinx raised?
NanoSyrinx has raised a total of $21.5M across 2 funding rounds:
Angel/Seed
$8.5M
Other Financing Round
$13M
Angel/Seed (2021): $8.5M with participation from Merck Ventures
Other Financing Round (2024): $13M led by Octopus Ventures and BGF
Key Investors in NanoSyrinx
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, focusing on early-stage investments and company creation to leverage scientific innovation.
Octopus Ventures
A founder-focused venture capital firm that provides long-term capital and guidance to mission-driven companies across the health, software, and climate sectors.
BGF
BGF is a prominent UK-based investor specializing in providing growth capital to small and mid-sized businesses across diverse economic sectors.
What's next for NanoSyrinx?
With the infusion of this latest capital, NanoSyrinx is well-positioned to accelerate its research and development pipeline, moving closer to clinical validation of its nanosyringe technology. The strategic focus will likely shift toward scaling its manufacturing capabilities and expanding its portfolio of therapeutic candidates. As the company navigates the complexities of the biotech sector, the support from its diverse investor base provides not only the necessary financial runway but also the operational expertise required to navigate regulatory hurdles and commercialization pathways. Future milestones will likely center on demonstrating the platform's versatility across various disease indications, further solidifying its market position as a leader in intracellular drug delivery.
See full NanoSyrinx company page
